Following is a transcript of their remarks:
Susan O Brien, MD: Hi, everyone, and welcome to this roundtable where we re going to discuss CLL presentations at ASH 2020 this year. I m Dr. Susan O Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I m joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
We have two presentations today on the TRANSCEND clinical trial, and that is an interesting CAR-T trial of liso-cel which targets CD19, like many of the other CAR-Ts, but is a little bit different in that it has a defined component of CD4 and CD8 cells, which I think is the only CAR-T that s actually doing that. One of the presentations involved just the CAR-T alone and the other was the CAR-T given in combination with ibrutinib. Jennifer, maybe you could speak to that and the rationale for actually giving it with ibrutinib in the sense that many of the patients had
Following is a transcript of their remarks:
Susan O Brien, MD: Hi, everyone, and welcome to this roundtable where we re going to discuss CLL presentations at ASH 2020 this year. I m Dr. Susan O Brien from the Chao Family Comprehensive Cancer Center at the University of California in Irvine, and I m joined by two esteemed colleagues, Dr. Jennifer Brown from Dana-Farber and Dr. Anthony Mato from Memorial Sloan Kettering.
An interesting presentation at ASH this year that many people were looking forward to was the trial looking at the combination of what s called U2, which is a novel anti-CD20 antibody, ublituximab, combined with a novel PI3K delta inhibitor, umbralisib. In this randomized trial, the comparator arm was obinutuzumab with chlorambucil and it was interesting because the trial actually included both previously untreated as well as previously treated patients. Jennifer, do you want to talk about some of the results from this trial?
At December s has brought together three expert leaders in their field:
Moderator Susan O Brien, MD, of Chao Family Comprehensive Cancer Center, University of California Irvine Health, is joined by Jennifer R. Brown, MD, Director of the CLL Center at Dana-Farber Cancer Institute, and Anthony Mato, MD, Director of the CLL Program at Memorial Sloan Kettering Cancer Center, for a virtual roundtable discussion on the new and potentially practice-changing data from the meeting.
In this first of four exclusive MedPage Today
episodes, the discussion centers on the studies focused on combined ibrutinib plus venetoclax therapy, including the phase II CAPTIVATE study.